CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy

AIDS

Volumn 14, Issue 2, 2000, Pages 173-180

  Torriani, Francesca J ^a,e   Freeman, William R ^b   Macdonald, J Christopher ^b   Karavellas, Marietta P ^b   Durand, Deborah M ^c   Jeffrey, Douglas D ^c   Meylan, Pascal R A ^d   Schrier, Rachel D ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytomegalovirus maintenance discontinuation; Cytomegalovirus specific responses; Highly active antiretroviral therapy responders; Prognostic factors of reactivation; Reactivation of cytomegalovirus disease

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CIDOFOVIR; GANCICLOVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; PANCREATITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETINITIS; VIRUS REACTIVATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; FEMALE; HIV; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; RNA, VIRAL; T-LYMPHOCYTES; TREATMENT FAILURE; VIRAL LOAD;

EID: 0034004058     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00013     Document Type: Article

References (26)

1. 1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see Comments], N Engl J Med 1997, 337:725-733.
2. 3. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC; 1997:207 [abstract LB7].
3. 3. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3:533-540.
4. 4. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease [see Comments]. Science 1997, 277:112-116.
5. 5. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [see Comments]. N Engl J Med 1997, 337:734-739.
6. 6. Baril L, Jouan M, Caumes E, Mengual X, Bricaire F, Katlama C. The impact of highly active antiretroviral therapy on the incidence of CMV disease in AIDS patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997:248 [abstract 1-31].
7. 7. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. N Engl J Med 1998, 338:853-860.
8. 8. Jacobson MA, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 1998, 12 (Suppl. A):S157-163.
9. 9. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study [see Comments]. N Engl J Med 1999, 340:1301-1306.
10. 10. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989, 107:75-80.
11. 11. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group [see Comments]. J Infect Dis 1992, 166:1223-1227.
12. 12. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998, 177:1080-1083.
13. 13. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998, 177:1182-1187.
14. 14. Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998, 105:1259-1264.
15. 15. Jabs DA, Bolton SC, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998, 126:817-822.
16. 16. Jouan M, Saves M, Tubiana R, et al. RESTIMOP (ANRS 078): a prospective multicentre study to evaluate the discontinuation of maintenance therapy for CMV retinitis in HIV-patients receiving HAART. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL; 1999:153 [abstract A56].
17. 17. SOCA. Assessment of cytomegalovirus retinitis. Clinical evaluation vs. centralized grading of fundus photographs. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Arch Ophthalmol 1996, 114:791-805.
18. 18. Chatellard P, Sahli R, Iten A, von Overbeck J, Meylan PR. Single tube competitive PCR for quantitation of CMV DNA in the blood of HIV+ and solid organ transplant patients. J Virol Methods 1998, 71:137-146.
19. 19. Schrier RD, Wiley CA, Spina C, McCutchan JA, Grant I. Pathogenic and protective correlates of T cell proliferation in AIDS. J Clin Invest 1996, 98:731-740.
20. 20. Afifi AA, Clark V. Discriminant analysis. In: Computer-aided multivariate analysis. Edited by Chapman and Hall. New York: Reinhold; 1990. pp. 271-314.
21. 21. Smith IL, Macdonald JC, Freeman WR, Shapiro AM, Spector SA. Cytomegalovirus (CMV) retinitis activity is accurately reflected by the presence and level of CMV DNA in aqueous humor and vitreous. J Infect Dis 1999, 179:1249-1253.
22. 22. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of Cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993, 115:575-582.
23. 23. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998, 101:497-502.
24. 24. McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS, Clin Infect Dis 1995, 20:747-754.
25. 25. Schrier RD, Freeman WR, Wiley CA, McCutchan JA. Immune predispositions for cytomegalovirus retinitis in AIDS. J Clin Invest 1995, 95:1741-1746.
26. 26. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998, 4:953-956.